Genetic Profiles of Plasmodium falciparum Isolates from a Therapeutic Efficacy Study on the Antimalarial Drug Dihydroartemisinin-Piperaquine in the West Sumba and Kupang Districts of East Nusa Tenggara Province, Indonesia
Authors:
- IrdayantiIRIrdayanti
- Hijral AswadHAHijral Aswad
- Puji Bs AsihPAPuji Bs Asih
- Ismail E. RoziIRIsmail E. Rozi
- Herdiana H. BasriHBHerdiana H. Basri
- Ajib DiptyanusaADAjib Diptyanusa
- Helen D. PrameswariHPHelen D. Prameswari
- Yenni YusufYYYenni Yusuf
- BahraniBABahrani
- Najdah HidayahNHNajdah Hidayah
- I Made ArtikaIAI Made Artika
- Din SyafruddinDSDin Syafruddin
Open Access
- 12 August 2025
- journal article
- research article
- Published by EDP Sciences in BIO Web of Conferences
- Vol. 184, 01018
Abstract
Artemisinin resistance, first reported on the Thai-Cambodian border in 2009, has spread across Southeast Asia, characterized by delayed parasite clearance. Extended artemisinin-based combination therapy (ACT) regimens have shown efficacy where standard 3-day treatments failure. In Indonesia, dihydroartemisinin-piperaquine (DHA-PPQ) has been the first-line treatment for uncomplicated Plasmodium falciparum malaria since 2010. This study evaluates the efficacy, safety, and parasite clearance times of DHA-PPQ in West Sumba and Kupang Districts, East Nusa Tenggara, while assessing single-nucleotide polymorphisms (SNPs) in the Pfk13 and Pfcrt genes, which are linked to artemisinin and piperaquine resistance, respectively. Following WHO guidelines, 382 cases were screened, with 41 eligible for 42-day clinical and parasitological monitoring. Molecular analyses utilized PCR and real-time PCR. All cases demonstrated adequate clinical and parasitological response (100% APCR). No mutations were detected in 21 Pfk13 SNPs associated with artemisinin resistance or in Pfcrt codons M343L, C350R, G353V, and I356L linked to piperaquine resistance. However, 10 of 41 samples (24.39%) exhibited Pfpm2 gene amplification, indicating early piperaquine selection pressure. DHA-PPQ remains effective, but Pfpm2 amplification underscores the need for continuous molecular surveillance and exploration of extended ACT regimens to sustain malaria control.Keywords
This publication has 12 references indexed in Scilit:
- Low prevalence of copy number variation in pfmdr1 and pfpm2 in Plasmodium falciparum isolates from southern AngolaMalaria Journal, 2025
- Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin–piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in IndonesiaMalaria Journal, 2023
- Molecular surveillance of artemisinin resistance-related Pfk13 and pfcrt polymorphisms in imported Plasmodium falciparum isolates reported in eastern China from 2015 to 2019Malaria Journal, 2022
- Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in IndonesiaMalaria Journal, 2022
- Evaluations of candidate markers of dihydroartemisinin-piperaquine resistance in Plasmodium falciparum isolates from the China–Myanmar, Thailand–Myanmar, and Thailand–Cambodia bordersParasites & Vectors, 2022
- Efficacy and safety of dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, IndonesiaMalaria Journal, 2022
- A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association studyThe Lancet Infectious Diseases, 2017
- A Worldwide Map ofPlasmodium falciparumK13-Propeller PolymorphismsNew England Journal of Medicine, 2016
- Artemisinin Resistance inPlasmodium falciparumMalariaNew England Journal of Medicine, 2009
- Mutations in the P. falciparum Digestive Vacuole Transmembrane Protein PfCRT and Evidence for Their Role in Chloroquine ResistanceMolecular Cell, 2000